Attributable mortality from extensively drug-resistant gram-negative infections using propensity-matched tracer antibiotic algorithms - 23/08/19
, Jeffrey R. Strich, MD, MS a, c, Bruce J. Swihart, PhD d, Samuel Hohmann, PhD e, f, John P. Dekker, MD, PhD g, Tara Palmore, MD h, Stephanie Bonne, MD i, Bradley Freeman, MD j, Jillian Raybould, MD k, l, Nirav G. Shah, MD m, Devang Patel, MD n, Jennifer Husson, MD, MPH n, Mitchell D. Jacobs, MD o, p, Lan Duong, PharmD q, Dean Follmann, PhD d, David C. Hooper, MD b, Joseph Timpone, MD k, Robert L. Danner, MD aHighlights |
• | Antibiotic algorithms allow estimation of attributable mortality (AM) from resistance. |
• | Estimated AM for extensively drug-resistant (XDR) gram-negative infections was 12.6%. |
• | AM of XDR gram-negative infections varied by site, onset, and severity of infection. |
• | Direct hospitalization costs attributed to XDR infection exceed $35,000 per encounter. |
Résumé |
Background |
Tracer antibiotic algorithms using administrative data were investigated to estimate mortality attributable to extensively drug-resistant gram-negative infections (GNIs).
Methods |
Among adult inpatients coded for GNIs, colistin cases and 2 comparator cohorts (non-carbapenem β-lactams or carbapenems) treated for ≥4 consecutive days, or died while receiving the antibiotic, were separately propensity score-matched (1:2). Attributable mortality was the in-hospital mortality difference among propensity-matched groups. Infection characteristics and sepsis severity influences on attributable mortality were examined. Algorithm accuracy was assessed by chart review.
Results |
Of 232,834 GNIs between 2010 and 2013 at 79 hospitals, 1,023 per 3,350 (30.5%) colistin and 9,188 per 105,641 (8.7%) β-lactam (non-carbapenem) comparator cases died. Propensity-matched colistin and β-lactam case mortality was 29.2% and 16.6%, respectively, for an attributable mortality of 12.6% (95% confidence interval 10.8-14.4%). Attributable mortality varied from 11.0% (7.5%-14.7%) for urinary to 15.5% (12.6%-18.4%) for respiratory (P < .0001), and 4.6% (2.1%-7.4%) for early (≤4 days) to 16.6% (14.3%-18.9%) for late-onset infections (P < .0001). Attributable mortality decreased to 7.5% (5.6%-9.4%) using a carbapenem comparator cohort but increased 9-fold in patients coded for severe sepsis or septic shock (P < .0001). Our colistin algorithm had a positive predictive value of 60.4% and sensitivity of 65.3%.
Conclusions |
Mortality attributable to treatment-limiting resistance during GNIs varied considerably by site, onset, and severity of infection.
Le texte complet de cet article est disponible en PDF.Key Words : Pharmacoepidemiology, Outcomes, Clinical impact, Big data, Cost, Colistin
Plan
| Funding/support: This research was supported by the Intramural Research Program of the National Institutes of Health. |
|
| Conflicts of interest: None to report. |
|
| The opinions expressed in this article are those of the authors and do not represent any position or policy of the National Institutes of Health, the US Department of Health and Human Services, or the US government. |
Vol 47 - N° 9
P. 1040-1047 - septembre 2019 Retour au numéro
Article précédent
- APIC Awards: Recognition for Those Advancing Infection Prevention
- Preliminary analysis of the antimicrobial activity of a postoperative wound dressing containing chlorhexidine gluconate against methicillin-resistant Staphylococcus aureus in an in vivo porcine incisional wound model
- Thriveen Sankar Chittoor Mana, Curtis Donskey, Neal Carty, Larry Perry, David Leaper, Charles E. Edmiston
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?